Loading clinical trials...

NOT_YET_RECRUITINGNA

Photobiomodulation for Cancer-Related Cognitive Impairment

Pilot Study of Photobiomodulation for Cancer-Related Cognitive Impairment

NCT05855694•Arash Asher, MD

Summary

This is a single site, pilot randomized, double blinded control trial designed to assess changes in cognitive symptoms in cancer survivors with cancer-related cognitive impairment. Patients will be randomized into one of two Arms: Intervention or Control. * Arm A: Intervention Group: Use of the THOR LED Photobiomodulation helmet 3x per week for 6 weeks. Helmet will be in 'therapeutic setting', 35mW/cm2 = 42J/cm2 * Arm B: Control Group: Use of the THOR LED Photobiomodulation helmet 3x per week for 6 weeks. Helmet will be in 'placebo setting', 0mW/cm2 = 0J/cm2 This study has been designed to assess the hypothesis that Photobiomodulation can have a positive impact on cognitive symptoms in cancer survivors with cancer-related cognitive impairment. 30 participants will be recruited for this study, 15 per group. Self-report questionnaires assessing cognitive concerns, cognitive abilities, quality of life, depression, and anxiety will be administered at three timepoints through the study Baseline, End of Study Visit and 1 Month Follow Up

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adults ≥ 18 years
•Previous diagnosis of stage I-III non-central nervous system solid tumor malignancy, Hodgkin, or Non-Hodgkin lymphoma
•Completed cancer treatment (chemotherapy and/or radiation) more than 6 months ago but less than 5 years ago (Current concurrent endocrine therapy, anti-HER-2 therapy allowed, or other stable maintenance therapies (such as rituximab) will be allowed.
•Self-reported cognitive complaints (score ≤ 54 on the Functional Assessment of Cancer Therapy-Cognition, Version 3, Perceived Cognitive Impairment subscale)
•Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
•Ability to read, write and understand either English OR Spanish.

Exclusion Criteria

•Current pregnancy or nursing status
•Current use of Photobiomodulation (PBM) (for any reason)
•A lifetime history of any brain tumor or central nervous system metastasis
•Previous use of intrathecal chemotherapy, chimeric antigen receptor treatment (CAR-T), or stem cell/marrow transplant
•Known history of other neurological conditions involving impaired cognitive function (such as Alzheimer's Disease and related dementias, Parkinson's Disease, or Multiple Sclerosis).

Locations (1)

Clinical Trial Recruitment Navigator

Los Angeles, California, United States

Key Dates

Start Date

April 1, 2026

Primary Completion Date

April 1, 2028

Completion Date

April 1, 2029

Last Updated

January 8, 2026

Enrollment

ESTIMATED participants

Conditions

Cancer-related Cognitive Impairment

Interventions

THOR LED Photobiomodulation Helmet - Therapeutic

DEVICE

THOR LED Photobiomodulation Helmet - Control

DEVICE

Contacts

Arash Asher, MD

CONTACT

424-315-0250 arash.asher@cshs.org

Cancer Clinical Trials Office

CONTACT

3104232133 Cancer.Trials.Info@cshs.org

Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairment (CRCI)

NCT05186948

Cancer-related Cognitive Impairment

View study

COMPLETED

Testosterone, Cognition, Ageing, and Cancer

NCT03452436

Cancer-related Cognitive Impairment

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 8, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions